RxDoctor Payments Data

Princy Kumar

Infectious Disease · Washington, DCNPI 1790784957

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $180,241 of the $269,964 with a category attached, or 66.8%. 10 manufacturers reported payments, led by Merck at 38.7% of the total. Reporting peaked in 2019 at $65,525 and has fallen 57.5% since, to $27,877 in 2025. Among infectious disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$269,964in general payments, 2019–2025

Across 283 payments — averaging $953.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$105K
  • Viiv Healthcare Company$82K
  • Gilead$38K
  • Theratechnologies Inc.$19K
  • Shionogi Inc$9K
  • Amgen$6K
  • plus $11K from 4 others
$4,231,227in research payments, 2019–2025

Across 578 payments — averaging $7320.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$945K
  • Eli Lilly$645K
  • Pfizer$588K
  • Theratechnologies Inc.$571K
  • Viiv Healthcare Company$535K
  • Merck$438K
  • plus $510K from 10 others

What the payments were for

  • Royalty or licence$9300%
  • Consulting fees$180,24167%
  • Speaking & faculty fees$36,40013%
  • Travel & lodging$46,88717%
  • Food & beverage$5,4852%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$269,964 in reported general payments places this provider in the 95th percentile of 74 infectious disease providers in District of Columbia.

See all infectious disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$62,835
Medicare patients
166
Services billed
433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala35$181,832
DescovyEmtricitabine/Tenofov Alafenam50$128,763
JulucaDolutegravir/Rilpivirine39$127,344
TivicayDolutegravir Sodium48$124,385
TriumeqAbacavir/Dolutegravir/Lamivudi17$113,069
PrezcobixDarunavir/Cobicistat21$52,822
CompleraEmtricita/Rilpivirine/Tenof Df11$39,214
DovatoDolutegravir Sodium/Lamivudine12$34,931
IsentressRaltegravir Potassium13$24,942
Testosterone11$500
Chlorthalidone13$106
Atorvastatin Calcium19$77
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$75
Allopurinol14$54
Lisinopril15$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Dovato$81,930$399,728116 claims
GileadBiktarvy, Descovy$38,345$310,59585 claims
MerckIsentress$104,569$24,94213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 infectious disease providers in District of Columbia.

Other infectious disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →